You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcebutolol
Accession NumberDB01193  (APRD00772)
TypeSmall Molecule
GroupsApproved
DescriptionA cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. [PubChem]
Structure
Thumb
Synonyms
(+-)-Acebutolol
(±)-acebutolol
3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide
5'-butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone
Acebutolol
Acebutololum
Acetobutolol
N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide
N-[3-Acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AcebutololTablet200 mgOralSanis Health Inc2010-02-25Not applicableCanada
AcebutololTablet100 mgOralSanis Health Inc2010-02-25Not applicableCanada
AcebutololTablet400 mgOralSanis Health Inc2010-02-25Not applicableCanada
Acebutolol - 400 - Tab 400mgTablet400 mgOralPro Doc Limitee1996-12-31Not applicableCanada
Acebutolol-100-tab 100mgTablet100 mgOralPro Doc Limitee1996-12-31Not applicableCanada
Acebutolol-200 - Tab 200mgTablet200 mgOralPro Doc Limitee1996-12-31Not applicableCanada
Ava-acebutololTablet100 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-acebutololTablet200 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-acebutololTablet400 mgOralAvanstra Inc2011-10-112014-08-21Canada
Monitan 100Tablet100 mgOralWyeth Canada1995-12-312004-09-13Canada
Monitan 200Tablet200 mgOralWyeth Canada1995-12-312007-01-22Canada
Monitan 400Tablet400 mgOralWyeth Canada1994-12-312007-01-22Canada
Monitan Tab 200mgTablet200 mgOralWyeth Ltd.1987-12-311996-09-10Canada
Monitan Tab 400mgTablet400 mgOralWyeth Ltd.1990-12-311996-09-10Canada
Mylan-acebutololTablet200 mgOralMylan Pharmaceuticals Ulc1998-04-06Not applicableCanada
Mylan-acebutololTablet400 mgOralMylan Pharmaceuticals Ulc1998-04-06Not applicableCanada
Mylan-acebutololTablet100 mgOralMylan Pharmaceuticals Ulc1998-04-06Not applicableCanada
Mylan-acebutolol (type S)Tablet400 mgOralMylan Pharmaceuticals Ulc1998-09-16Not applicableCanada
Mylan-acebutolol (type S)Tablet100 mgOralMylan Pharmaceuticals Ulc1998-09-16Not applicableCanada
Mylan-acebutolol (type S)Tablet200 mgOralMylan Pharmaceuticals Ulc1998-09-16Not applicableCanada
Novo-acebutolol (type S)Tablet100 mgOralNovopharm LimitedNot applicableNot applicableCanada
Novo-acebutolol (type S)Tablet200 mgOralNovopharm LimitedNot applicableNot applicableCanada
Novo-acebutolol (type S)Tablet400 mgOralNovopharm LimitedNot applicableNot applicableCanada
Nu-acebutolol - Tab 100mgTablet100 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-acebutolol - Tab 200mgTablet200 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-acebutolol - Tab 400mgTablet400 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Penta-acebutolol TabletsTablet100 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-acebutolol TabletsTablet200 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-acebutolol TabletsTablet400 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Rhotral 100Tablet100 mgOralSanofi Aventis Canada Inc1991-12-312010-10-26Canada
Rhotral 200Tablet200 mgOralSanofi Aventis Canada Inc1991-12-312010-10-26Canada
Rhotral 400Tablet400 mgOralSanofi Aventis Canada Inc1995-12-312011-01-06Canada
Sandoz AcebutololTablet100 mgOralSandoz Canada Incorporated2004-08-18Not applicableCanada
Sandoz AcebutololTablet200 mgOralSandoz Canada Incorporated2004-08-18Not applicableCanada
Sandoz AcebutololTablet400 mgOralSandoz Canada Incorporated2004-08-18Not applicableCanada
SectralCapsule200 mg/1OralPromius Pharma, LLC1984-12-28Not applicableUs
SectralTablet400 mgOralSanofi Aventis Canada Inc1990-12-31Not applicableCanada
SectralCapsule400 mg/1OralPromius Pharma, LLC1984-12-28Not applicableUs
SectralTablet100 mgOralSanofi Aventis Canada Inc1986-12-31Not applicableCanada
SectralTablet200 mgOralSanofi Aventis Canada Inc1986-12-31Not applicableCanada
Teva-acebutololTablet200 mgOralTeva Canada Limited1996-08-16Not applicableCanada
Teva-acebutololTablet100 mgOralTeva Canada Limited1996-08-16Not applicableCanada
Teva-acebutololTablet400 mgOralTeva Canada Limited1996-08-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acebutolol HydrochlorideCapsule200 mg/1Oralbryant ranch prepack2009-12-01Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1OralMylan Pharmaceuticals Inc.1995-04-24Not applicableUs
Acebutolol HydrochlorideCapsule400 mg/1OralAv Kare, Inc.2009-12-14Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1OralAmneal Pharmaceuticals of New York, LLC2009-12-01Not applicableUs
Acebutolol HydrochlorideCapsule400 mg/1OralMylan Pharmaceuticals Inc.1995-04-24Not applicableUs
Acebutolol HydrochlorideCapsule400 mg/1OralAv Pak2009-12-012016-10-13Us
Acebutolol HydrochlorideCapsule400 mg/1OralAmneal Pharmaceuticals of New York, LLC2009-12-01Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1OralMajor Pharmaceuticals2009-12-01Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1OralAv Pak2009-12-01Not applicableUs
Acebutolol HydrochlorideCapsule400 mg/1OralPhysicians Total Care, Inc.2005-04-22Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1OralAv Kare, Inc.2009-12-14Not applicableUs
Apo-acebutololTablet200 mgOralApotex Inc1995-12-31Not applicableCanada
Apo-acebutololTablet400 mgOralApotex Inc1995-12-31Not applicableCanada
Apo-acebutololTablet100 mgOralApotex Inc1995-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PrentBayer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Acebutolol Hydrochloride
34381-68-5
Thumb
  • InChI Key: KTUFKADDDORSSI-UHFFFAOYSA-N
  • Monoisotopic Mass: 372.181585133
  • Average Mass: 372.887
DBSALT000192
Categories
UNII67P356D8GH
CAS number37517-30-9
WeightAverage: 336.4259
Monoisotopic: 336.204907394
Chemical FormulaC18H28N2O4
InChI KeyGOEMGAFJFRBGGG-UHFFFAOYSA-N
InChI
InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
IUPAC Name
N-(3-acetyl-4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)butanamide
SMILES
CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1
Pharmacology
IndicationFor the management of hypertension and ventricular premature beats in adults.
Structured Indications
PharmacodynamicsAcebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. In general, beta-blockers reduce the work the heart has to do and allow it to beat more regularly. Acebutolol has less antagonistic effects on peripheral vascular ß2-receptors at rest and after epinephrine stimulation than nonselective beta-antagonists. Low doses of acebutolol produce less evidence of bronchoconstriction than nonselective agents like propranolol but more than atenolol.
Mechanism of actionAcebutolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors, lowering the heart rate and blood pressure. This drug then has the reverse effect of epinephrine. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
partial agonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
partial agonist
HumanP07550 details
Related Articles
AbsorptionWell absorbed from the Gl tract with an absolute bioavailability of approximately 40% for the parent compound. In
Volume of distributionNot Available
Protein binding26%
Metabolism

Subject to extensive first-pass hepatic biotransformation (primarily to diacetolol).

Route of eliminationElimination via renal excretion is approximately 30% to 40% and by non-renal mechanisms 50% to 60%, which includes excretion into the bile and direct passage through the intestinal wall.
Half lifeThe plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include extreme bradycardia, advanced atrioventricular block, intraventricular conduction defects, hypotension, severe congestive heart failure, seizures, and in susceptible patients, bronchospasm, and hypoglycemia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Acebutolol Action PathwayDrug actionSMP00296
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Acebutolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Acebutolol.Experimental
AceclofenacAceclofenac may decrease the antihypertensive activities of Acebutolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Acebutolol.Approved
AcetaminophenThe serum concentration of Acebutolol can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideAcebutolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Acebutolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Acetylcholine.Approved
AcetyldigitoxinAcebutolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Acebutolol.Approved
AfatinibThe serum concentration of Acebutolol can be increased when it is combined with Afatinib.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Experimental, Investigational
AlbendazoleThe serum concentration of Acebutolol can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.Approved
AldosteroneThe serum concentration of Acebutolol can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Acebutolol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Acebutolol can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Acebutolol is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Acebutolol.Approved, Withdrawn
AmantadineThe serum concentration of Acebutolol can be increased when it is combined with Amantadine.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Acebutolol.Approved
AmbrisentanAcebutolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateAcebutolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineAcebutolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Acebutolol.Approved
Aminohippuric acidThe serum concentration of Acebutolol can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineAcebutolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Acebutolol.Approved, Investigational
AmitriptylineThe serum concentration of Acebutolol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Acebutolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Acebutolol.Approved, Illicit
AmodiaquineThe metabolism of Acebutolol can be decreased when combined with Amodiaquine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Acebutolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Acebutolol is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Acebutolol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Acebutolol can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Acebutolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Acebutolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Acebutolol.Approved
AnvirzelAcebutolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Acebutolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
ArbutamineAcebutolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Arecoline.Experimental
ArformoterolAcebutolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Acebutolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Acebutolol can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Acebutolol can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Acebutolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Acebutolol.Approved
AtorvastatinThe serum concentration of Acebutolol can be increased when it is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Acebutolol.Withdrawn
AzelastineThe serum concentration of Acebutolol can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Acebutolol is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Acebutolol can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
BambuterolAcebutolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Acebutolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Acebutolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Acebutolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acebutolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Acebutolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Acebutolol.Withdrawn
BenzocaineThe serum concentration of Acebutolol can be increased when it is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Illicit
BepridilThe serum concentration of Acebutolol can be increased when it is combined with Bepridil.Approved, Withdrawn
BeractantAcebutolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Acebutolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Acebutolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Acebutolol.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Acebutolol.Approved, Investigational
BiperidenThe serum concentration of Acebutolol can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acebutolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Acebutolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Acebutolol is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Acebutolol.Approved, Investigational
BosutinibThe serum concentration of Acebutolol can be increased when it is combined with Bosutinib.Approved
BretyliumBretylium may increase the bradycardic activities of Acebutolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Acebutolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Acebutolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Acebutolol.Investigational
BucindololAcebutolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Acebutolol.Approved, Investigational
BupranololAcebutolol may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Acebutolol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Acebutolol can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Acebutolol can be increased when it is combined with Cabazitaxel.Approved
CabergolineAcebutolol may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe serum concentration of Acebutolol can be increased when it is combined with Caffeine.Approved
CalfactantAcebutolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Acebutolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Acebutolol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Acebutolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Acebutolol is combined with Carbachol.Approved
CarbamazepineThe serum concentration of Acebutolol can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Acebutolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Acebutolol.Approved
CarvedilolAcebutolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Acebutolol can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may decrease the antihypertensive activities of Acebutolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
CeliprololAcebutolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibAcebutolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cevimeline.Approved
ChloroquineThe serum concentration of Acebutolol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acebutolol.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Acebutolol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Acebutolol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Acebutolol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acebutolol.Approved
CholesterolThe serum concentration of Acebutolol can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Acebutolol can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Acebutolol can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Acebutolol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Acebutolol can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Acebutolol can be increased when it is combined with Clarithromycin.Approved
ClenbuterolAcebutolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Acebutolol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Acebutolol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Acebutolol.Approved
ClotrimazoleThe serum concentration of Acebutolol can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clozapine.Approved
CobicistatThe serum concentration of Acebutolol can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Acebutolol can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Acebutolol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe risk or severity of adverse effects can be increased when Acebutolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Acebutolol.Vet Approved
CrizotinibThe serum concentration of Acebutolol can be increased when it is combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Acebutolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Acebutolol.Investigational
CyclophosphamideThe serum concentration of Acebutolol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Acebutolol can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Acebutolol.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Acebutolol.Investigational
DaclatasvirThe serum concentration of Acebutolol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Acebutolol can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Acebutolol can be increased when it is combined with Dapoxetine.Investigational
DasatinibThe serum concentration of Acebutolol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Acebutolol can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinAcebutolol may increase the hypotensive activities of Debrisoquin.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Acebutolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Acebutolol.Approved
DeserpidineAcebutolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Acebutolol is combined with Desflurane.Approved
DesipramineThe serum concentration of Acebutolol can be increased when it is combined with Desipramine.Approved
DeslanosideAcebutolol may increase the bradycardic activities of Deslanoside.Approved
DesloratadineThe serum concentration of Acebutolol can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Acebutolol can be increased when it is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Acebutolol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Vet Approved
DextromethorphanThe serum concentration of Acebutolol can be increased when it is combined with Dextromethorphan.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Acebutolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Acebutolol.Vet Approved
DiclofenacThe serum concentration of Acebutolol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Acebutolol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Acebutolol.Approved
DigitoxinAcebutolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinThe serum concentration of Acebutolol can be decreased when it is combined with Digoxin.Approved
DihydralazineAcebutolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Acebutolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Acebutolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Acebutolol.Approved
DobutamineAcebutolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Acebutolol.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Acebutolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Acebutolol.Approved
DoxazosinAcebutolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe serum concentration of Acebutolol can be increased when it is combined with Doxepin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Doxofylline.Approved
DoxorubicinThe serum concentration of Acebutolol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Acebutolol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Acebutolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Acebutolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
DuloxetineAcebutolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Acebutolol.Investigational
DyphyllineAcebutolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Acebutolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Acebutolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Acebutolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Acebutolol.Approved
EfonidipineAcebutolol may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Acebutolol can be increased when it is combined with Elbasvir.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Acebutolol.Approved, Vet Approved
EnalaprilatAcebutolol may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Acebutolol can be increased when it is combined with Enzalutamide.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Nutraceutical, Withdrawn
EphedrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Ephedrine.Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Acebutolol is combined with EPIBATIDINE.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Acebutolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Acebutolol.Approved
EpoprostenolAcebutolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acebutolol.Approved
Ergoloid mesylateAcebutolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineAcebutolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
ErythromycinThe serum concentration of Acebutolol can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Acebutolol.Approved
EstramustineThe serum concentration of Acebutolol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Acebutolol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Acebutolol can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
EtilefrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Etilefrine.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Acebutolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
EtoperidoneThe serum concentration of Acebutolol can be increased when it is combined with Etoperidone.Approved
EtoposideThe serum concentration of Acebutolol can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
EtravirineThe serum concentration of Acebutolol can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Acebutolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Acebutolol.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Acebutolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Acebutolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Acebutolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Acebutolol.Approved
FenoterolAcebutolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylThe serum concentration of Acebutolol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Acebutolol.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol.Approved
FexofenadineThe serum concentration of Acebutolol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Acebutolol can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Acebutolol is combined with Fimasartan.Approved
FingolimodAcebutolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Acebutolol.Approved, Withdrawn
FluconazoleThe serum concentration of Acebutolol can be increased when it is combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Acebutolol.Vet Approved
FluoxetineThe serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Acebutolol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Acebutolol can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Acebutolol can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
FluvoxamineThe serum concentration of Acebutolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolAcebutolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Acebutolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Acebutolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Acebutolol.Approved
GefitinibThe serum concentration of Acebutolol can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Acebutolol can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Acebutolol.Approved, Nutraceutical
GlibornurideAcebutolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideAcebutolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAcebutolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAcebutolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneAcebutolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideAcebutolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideThe serum concentration of Acebutolol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Acebutolol can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Acebutolol can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Acebutolol can be increased when it is combined with Grepafloxacin.Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Acebutolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Acebutolol.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Acebutolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
HaloperidolThe serum concentration of Acebutolol can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Acebutolol is combined with Halothane.Approved, Vet Approved
HexamethoniumAcebutolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Acebutolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Acebutolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Acebutolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Acebutolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Acebutolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acebutolol.Approved, Vet Approved
HydrocortisoneThe serum concentration of Acebutolol can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Acebutolol.Approved
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe metabolism of Acebutolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Acebutolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Acebutolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Acebutolol.Approved
IdelalisibThe serum concentration of Acebutolol can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Acebutolol.Approved, Investigational
ImatinibThe serum concentration of Acebutolol can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Acebutolol is combined with Imidapril.Investigational
ImipramineThe serum concentration of Acebutolol can be increased when it is combined with Imipramine.Approved
IndacaterolAcebutolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Acebutolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Acebutolol.Approved
IndenololAcebutolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Acebutolol can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Acebutolol can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Acebutolol.Withdrawn
IndoraminAcebutolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkAcebutolol may increase the hypoglycemic activities of Insulin Pork.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Acebutolol.Approved
IproclozideIproclozide may increase the hypotensive activities of Acebutolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Acebutolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Acebutolol.Approved, Investigational
IsavuconazoniumThe serum concentration of Acebutolol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Acebutolol.Approved
IsoetarineAcebutolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Acebutolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Acebutolol.Approved, Withdrawn
IsoprenalineAcebutolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Acebutolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Acebutolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Acebutolol.Approved
ItraconazoleThe serum concentration of Acebutolol can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineAcebutolol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Acebutolol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Acebutolol can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Acebutolol.Experimental
KetamineThe serum concentration of Acebutolol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinAcebutolol may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Acebutolol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Acebutolol.Approved
LabetalolAcebutolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineAcebutolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideAcebutolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideAcebutolol may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Acebutolol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Acebutolol can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Acebutolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Levobupivacaine.Approved
LevodopaAcebutolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Acebutolol can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Acebutolol is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Acebutolol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Acebutolol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinezolidLinezolid may increase the hypertensive activities of Acebutolol.Approved, Investigational
LiothyronineThe serum concentration of Acebutolol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Acebutolol can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Acebutolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Acebutolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
LomitapideThe serum concentration of Acebutolol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Acebutolol can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Acebutolol can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Acebutolol can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Acebutolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Acebutolol.Approved
LovastatinThe serum concentration of Acebutolol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Acebutolol.Approved
LucinactantAcebutolol may increase the bradycardic activities of Lucinactant.Approved
LumacaftorThe serum concentration of Acebutolol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
MacitentanAcebutolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Acebutolol.Approved
MalathionMalathion may increase the bradycardic activities of Acebutolol.Approved, Investigational
ManidipineAcebutolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.Approved, Investigational
MaprotilineThe serum concentration of Acebutolol can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Acebutolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Acebutolol.Withdrawn
MebendazoleThe serum concentration of Acebutolol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Acebutolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Acebutolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Acebutolol.Approved
Megestrol acetateThe serum concentration of Acebutolol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Acebutolol.Approved, Investigational
MephentermineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Mephentermine.Approved
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Acebutolol.Approved, Vet Approved
MeprobamateThe serum concentration of Acebutolol can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may decrease the antihypertensive activities of Acebutolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Acebutolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Acebutolol.Withdrawn
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Acebutolol.Approved, Investigational
MethacholineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Methacholine.Approved
MethadoneThe serum concentration of Acebutolol can be increased when it is combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Acebutolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Acebutolol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Acebutolol.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Acebutolol.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Acebutolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Acebutolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Acebutolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Acebutolol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Acebutolol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Acebutolol.Approved, Investigational
MetyrosineAcebutolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe serum concentration of Acebutolol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Acebutolol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Acebutolol can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineAcebutolol may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Acebutolol can be decreased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Acebutolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Acebutolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Acebutolol.Approved
MitomycinThe serum concentration of Acebutolol can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Acebutolol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Acebutolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Acebutolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Acebutolol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Acebutolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Acebutolol.Approved, Withdrawn
MorphineThe serum concentration of Acebutolol can be increased when it is combined with Morphine.Approved, Investigational
MoxonidineAcebutolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Acebutolol.Approved
NabiloneNabilone may increase the tachycardic activities of Acebutolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Acebutolol.Approved
NadololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Acebutolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Acebutolol.Approved
NaftopidilAcebutolol may increase the hypotensive activities of Naftopidil.Investigational
NaltrexoneThe serum concentration of Acebutolol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
NaringeninThe serum concentration of Acebutolol can be increased when it is combined with Naringenin.Experimental
NCX 4016NCX 4016 may decrease the antihypertensive activities of Acebutolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Acebutolol can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Acebutolol can be decreased when it is combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Acebutolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Acebutolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Acebutolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Acebutolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Acebutolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Acebutolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Acebutolol.Approved
NiguldipineAcebutolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Acebutolol can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineAcebutolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Acebutolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Acebutolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Acebutolol.Approved
NitrazepamThe serum concentration of Acebutolol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Acebutolol can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Acebutolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Acebutolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Acebutolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
NorethisteroneThe serum concentration of Acebutolol can be decreased when it is combined with Norethisterone.Approved
NylidrinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nylidrin.Approved
ObinutuzumabAcebutolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Acebutolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Acebutolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acebutolol.Approved, Investigational
OlodaterolAcebutolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Acebutolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Acebutolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Acebutolol.Investigational
OmeprazoleThe serum concentration of Acebutolol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineAcebutolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Acebutolol.Vet Approved
OuabainAcebutolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Acebutolol.Approved
OxprenololAcebutolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Acebutolol.Withdrawn
P-NitrophenolThe serum concentration of Acebutolol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Acebutolol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
Palmitic AcidThe serum concentration of Acebutolol can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Acebutolol can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Acebutolol.Approved
PargylinePargyline may increase the hypotensive activities of Acebutolol.Approved
ParoxetineThe serum concentration of Acebutolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideAcebutolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Acebutolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Acebutolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Acebutolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Acebutolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Acebutolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Acebutolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Acebutolol.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol.Approved, Illicit
PhenobarbitalThe serum concentration of Acebutolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Acebutolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Acebutolol.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Acebutolol.Approved, Illicit
PhentolaminePhentolamine may increase the hypotensive activities of Acebutolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Acebutolol.Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Acebutolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
PimozideThe serum concentration of Acebutolol can be increased when it is combined with Pimozide.Approved
PinacidilAcebutolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Acebutolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Acebutolol is combined with Pipamperone.Approved
PirbuterolAcebutolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Acebutolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Acebutolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Acebutolol.Withdrawn
Platelet Activating FactorThe serum concentration of Acebutolol can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideAcebutolol may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe serum concentration of Acebutolol can be increased when it is combined with Ponatinib.Approved
Poractant alfaAcebutolol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Acebutolol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Acebutolol is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Acebutolol can be increased when it is combined with Pravastatin.Approved
PrazosinAcebutolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrednisoneThe serum concentration of Acebutolol can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe metabolism of Acebutolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
ProbenecidThe serum concentration of Acebutolol can be increased when it is combined with Probenecid.Approved
ProcaterolAcebutolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
ProgesteroneThe serum concentration of Acebutolol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
PromethazineThe serum concentration of Acebutolol can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Acebutolol.Approved
PropafenoneThe serum concentration of Acebutolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Acebutolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Acebutolol.Approved, Investigational
ProtriptylineThe serum concentration of Acebutolol can be increased when it is combined with Protriptyline.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Acebutolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Acebutolol.Approved
QuercetinThe serum concentration of Acebutolol can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Acebutolol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Acebutolol.Approved, Investigational
QuinidineThe serum concentration of Acebutolol can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Acebutolol.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Racepinephrine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Acebutolol.Approved
RanitidineThe serum concentration of Acebutolol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Acebutolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Acebutolol.Approved
ReboxetineThe serum concentration of Acebutolol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Acebutolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Acebutolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Acebutolol.Approved
RescinnamineAcebutolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Acebutolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Acebutolol.Experimental, Investigational
RifampicinThe serum concentration of Acebutolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Acebutolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineAcebutolol may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Acebutolol can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Acebutolol is combined with Riociguat.Approved
RisperidoneAcebutolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineAcebutolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe serum concentration of Acebutolol can be decreased when it is combined with Ritonavir.Approved, Investigational
RituximabAcebutolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Acebutolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Acebutolol.Investigational, Withdrawn
RolapitantThe serum concentration of Acebutolol can be increased when it is combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Acebutolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Acebutolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Acebutolol.Withdrawn
SalbutamolAcebutolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Acebutolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
SalmeterolAcebutolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Acebutolol.Approved
SaprisartanAcebutolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Acebutolol can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Acebutolol can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
SelegilineThe serum concentration of Acebutolol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagAcebutolol may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
SertralineThe serum concentration of Acebutolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Acebutolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Acebutolol.Approved, Investigational
SilodosinAcebutolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SimeprevirThe serum concentration of Acebutolol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Acebutolol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Acebutolol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitaxentanAcebutolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Acebutolol is combined with Sodium Nitrite.Approved
SorafenibThe serum concentration of Acebutolol can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Acebutolol.Approved
SpiraprilAcebutolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Acebutolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Acebutolol.Investigational
St. John's WortThe serum concentration of Acebutolol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Acebutolol can be increased when it is combined with Staurosporine.Experimental
StreptokinaseThe risk or severity of adverse effects can be increased when Acebutolol is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Acebutolol can be decreased when it is combined with Streptozocin.Approved
SufentanilSufentanil may increase the bradycardic activities of Acebutolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Acebutolol.Approved
SulfinpyrazoneThe serum concentration of Acebutolol can be increased when it is combined with Sulfinpyrazone.Approved
SulindacSulindac may decrease the antihypertensive activities of Acebutolol.Approved
SumatriptanThe serum concentration of Acebutolol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Acebutolol can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Acebutolol.Approved, Withdrawn
SynephrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Acebutolol.Withdrawn
TacrolimusThe serum concentration of Acebutolol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Acebutolol.Approved, Investigational
TamoxifenThe serum concentration of Acebutolol can be decreased when it is combined with Tamoxifen.Approved
TamsulosinAcebutolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Acebutolol can be increased when it is combined with Taurocholic Acid.Experimental
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Acebutolol.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acebutolol.Approved, Investigational
TemocaprilAcebutolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Acebutolol can be increased when it is combined with Temsirolimus.Approved
TenoxicamTenoxicam may decrease the antihypertensive activities of Acebutolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Acebutolol.Vet Approved
TerazosinAcebutolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineAcebutolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerfenadineThe serum concentration of Acebutolol can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Acebutolol.Approved
TerlipressinAcebutolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Acebutolol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Acebutolol can be increased when it is combined with Testosterone.Approved, Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineAcebutolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Acebutolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Acebutolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Acebutolol.Approved
TiboloneAcebutolol may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Acebutolol can be increased when it is combined with Ticagrelor.Approved
TicrynafenAcebutolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Acebutolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Acebutolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Acebutolol.Approved, Investigational
TolazamideAcebutolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
TolbutamideAcebutolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Acebutolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Acebutolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Acebutolol.Approved
TolvaptanThe serum concentration of Acebutolol can be increased when it is combined with Tolvaptan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Acebutolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Acebutolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Acebutolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Acebutolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Acebutolol.Approved
TrazodoneThe serum concentration of Acebutolol can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Acebutolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Acebutolol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Acebutolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
TrifluoperazineThe serum concentration of Acebutolol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Acebutolol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinAcebutolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Acebutolol.Approved
TrimethoprimThe serum concentration of Acebutolol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Acebutolol can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Acebutolol.Approved
TroleandomycinThe serum concentration of Acebutolol can be increased when it is combined with Troleandomycin.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Acebutolol.Approved
TyramineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tyramine.Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Acebutolol.Approved, Investigational
UnoprostoneAcebutolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Acebutolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Acebutolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Acebutolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Acebutolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Acebutolol.Approved
VilanterolAcebutolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinblastineThe serum concentration of Acebutolol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Acebutolol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Acebutolol can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineAcebutolol may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Acebutolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Acebutolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Acebutolol.Withdrawn
Food Interactions
  • Take without regard to meals; absorption rate and maximal concentration are slightly reduced but the extent of absorption is not affected.
References
Synthesis Reference

DrugSyn.org

US3857952
General ReferencesNot Available
External Links
ATC CodesC07AB04C07BB04
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7378
P-glycoprotein inhibitor INon-inhibitor0.8557
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterNon-inhibitor0.9466
CYP450 2C9 substrateNon-substrate0.8102
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5752
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8721
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9639
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.849
BiodegradationNot ready biodegradable0.8538
Rat acute toxicity2.0487 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9821
hERG inhibition (predictor II)Non-inhibitor0.8555
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral200 mg/1
CapsuleOral400 mg/1
TabletOral100 mg
TabletOral200 mg
TabletOral400 mg
Prices
Unit descriptionCostUnit
Acebutolol hcl powder7.08USD g
Sectral 400 mg capsule4.48USD capsule
Sectral 200 mg capsule3.37USD capsule
Acebutolol HCl 400 mg capsule1.39USD capsule
Acebutolol 400 mg capsule1.34USD capsule
Sectral 400 mg Tablet1.11USD tablet
Acebutolol HCl 200 mg capsule1.05USD capsule
Acebutolol 200 mg capsule1.01USD capsule
Sectral 200 mg Tablet0.56USD tablet
Acebutolol 400 mg Tablet0.51USD tablet
Apo-Acebutolol 400 mg Tablet0.51USD tablet
Mylan-Acebutolol (Type S) 400 mg Tablet0.51USD tablet
Mylan-Acebutolol 400 mg Tablet0.51USD tablet
Novo-Acebutolol 400 mg Tablet0.51USD tablet
Nu-Acebutolol 400 mg Tablet0.51USD tablet
Rhotral 400 mg Tablet0.51USD tablet
Sectral 100 mg Tablet0.37USD tablet
Acebutolol 200 mg Tablet0.26USD tablet
Apo-Acebutolol 200 mg Tablet0.26USD tablet
Mylan-Acebutolol (Type S) 200 mg Tablet0.26USD tablet
Mylan-Acebutolol 200 mg Tablet0.26USD tablet
Novo-Acebutolol 200 mg Tablet0.26USD tablet
Nu-Acebutolol 200 mg Tablet0.26USD tablet
Rhotral 200 mg Tablet0.26USD tablet
Acebutolol 100 mg Tablet0.17USD tablet
Apo-Acebutolol 100 mg Tablet0.17USD tablet
Mylan-Acebutolol (Type S) 100 mg Tablet0.17USD tablet
Mylan-Acebutolol 100 mg Tablet0.17USD tablet
Novo-Acebutolol 100 mg Tablet0.17USD tablet
Nu-Acebutolol 100 mg Tablet0.17USD tablet
Rhotral 100 mg Tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point136-138Merck Index 13
water solubility259 mg/LNot Available
logP1.71HANSCH,C ET AL. (1995)
Caco2 permeability-5.83ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.172 mg/mLALOGPS
logP1.43ALOGPS
logP1.53ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.91ChemAxon
pKa (Strongest Basic)9.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area87.66 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity94.87 m3·mol-1ChemAxon
Polarizability38.51 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylamides. These are organic compounds that contain a carboxamide group that is N-linked to a aryl group. They have the generic structure RC(=O)N(R')H, R = organyl group and R'= aryl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassN-arylamides
Sub ClassNot Available
Direct ParentN-arylamides
Alternative Parents
Substituents
  • N-arylamide
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Fatty amide
  • Monocyclic benzene moiety
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Ketone
  • Carboxamide group
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. van den Meiracker AH, Man in 't Veld AJ, Fischberg DJ, Molinoff PB, van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA: Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density. J Cardiovasc Pharmacol. 1988 Apr;11(4):413-23. [PubMed:2453744 ]
  2. Abrahamsson T: Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70. Eur J Pharmacol. 1989 May 2;164(1):121-8. [PubMed:2568935 ]
  3. Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148 ]
  2. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]
  3. Lima JJ: Relationship between beta adrenoceptor occupancy and receptor down-regulation induced by beta antagonists with intrinsic sympathomimetic activity. J Recept Signal Transduct Res. 1996 Sep-Nov;16(5-6):357-72. [PubMed:8968966 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  2. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11